Regarding the tumor characteristics of patients with IBC (Group A) and DCIS (Group B), estrogen and progesterone receptor (ER/PR) positivity was observed in 76 (70.4%) patients in Group A and 81 (75%) patients in Group B, with no statistically significant difference between the groups. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.